Celldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed by HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $80.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 101.66% from the company’s current price.

Other research analysts also recently issued research reports about the company. Guggenheim boosted their price target on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. TD Cowen assumed coverage on Celldex Therapeutics in a research note on Wednesday, December 20th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock traded up $1.07 during trading hours on Wednesday, reaching $39.67. The company had a trading volume of 655,304 shares, compared to its average volume of 902,647. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18. The company has a 50-day moving average price of $41.98 and a 200 day moving average price of $35.68. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of -13.58 and a beta of 1.49.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The company had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. As a group, research analysts expect that Celldex Therapeutics will post -2.85 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CLDX. Wellington Management Group LLP boosted its stake in Celldex Therapeutics by 19.2% during the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after acquiring an additional 1,044,728 shares in the last quarter. Eventide Asset Management LLC boosted its position in shares of Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after purchasing an additional 2,030,013 shares in the last quarter. BlackRock Inc. grew its stake in shares of Celldex Therapeutics by 0.8% in the 1st quarter. BlackRock Inc. now owns 3,250,638 shares of the biopharmaceutical company’s stock worth $116,958,000 after buying an additional 25,922 shares during the last quarter. State Street Corp raised its stake in Celldex Therapeutics by 20.4% during the second quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock valued at $87,050,000 after buying an additional 546,124 shares during the last quarter. Finally, Kynam Capital Management LP raised its stake in Celldex Therapeutics by 23.1% during the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after buying an additional 600,000 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.